HALO logo
halo search icon
United Therapeutics Corporation
United Therapeutics Corporation
UTHR · NAS

United Therapeutics Corporation

US$565.87

Price Arrow1.94 (0.344%)
21/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusHALO 500HALO AllHALO Balance SheetHALO SmallHammer BullishHammer Bullish (Realtime)
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

United Therapeutics Corporation Overview

UTHR Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Neutral

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Neutral

Earnings

Neutral

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Strong

Balance Sheet

Very Strong

About UTHR

icon

Telephone

1.301.608.9292

icon

Address

1000 Spring Street, Silver Spring, MD 20910

Description

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

UTHR Price Chart

Key Stats

Market Cap

US$23.94B

PE

17.50

EV/EBITDA

12.7

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 272.12 - 609.35

Trade Value (12mth)

US$62,303,823.00

1 week

-0.82%

1 month

-1.8%

YTD

13.53%

1 year

82.67%

All time high

609.35

Key Fundamentals

EPS 3 yr Growth

88.50%

EBITDA Margin

50.40%

Operating Cashflow

$1,561m

Free Cash Flow Return

23.10%

ROIC

19.70%

Interest Coverage

82.20

Quick Ratio

6.30

Other Data

Shares Outstanding (Fully Diluted)

47m

HALO Sector

Healthcare

Next Company Report Date

24-Feb-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

UTHR Announcements

Latest Announcements

DateAnnouncements
06 May 26
06 May 26
06 May 26
30 March 26
10 March 26

UTHR Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock21.0426.4430.13locklocklock
EPS (Fully Diluted)
$locklocklocklock19.8124.6427.86locklocklock
Growth
%locklocklocklock31.625.713.9locklocklock
PE
Xlocklocklocklock11.114.317.5locklocklock
EV/EBITDA
Xlocklocklocklock79.812.7locklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of United Therapeutics Corporation (UTHR:NAS)?
Halo FAQ
The current share price of United Therapeutics Corporation (UTHR:NAS) is USD$565.87.
What is the 52-week high share price for United Therapeutics Corporation (UTHR:NAS)?
Halo FAQ
The 52-week high share price for United Therapeutics Corporation (UTHR:NAS) is USD$609.35.
What is the 52-week low share price for United Therapeutics Corporation (UTHR:NAS)?
Halo FAQ
The 52-week low share price for United Therapeutics Corporation (UTHR:NAS) is USD$272.12.
What is the dividend yield for United Therapeutics Corporation (UTHR:NAS)?
Halo FAQ
United Therapeutics Corporation (UTHR:NAS) does not pay a dividend.
What was United Therapeutics Corporation (UTHR:NAS) last dividend payment?
Halo FAQ
United Therapeutics Corporation (UTHR:NAS) does not pay a dividend.
What is the franking level for United Therapeutics Corporation (UTHR:NAS)?
Halo FAQ
United Therapeutics Corporation (UTHR:NAS) has a franking level of 0.00%.
In which sector is United Therapeutics Corporation (UTHR:NAS) classified?
Halo FAQ
United Therapeutics Corporation (UTHR:NAS) is classified in the Healthcare.
What is the price-to-earnings (P/E) ratio for United Therapeutics Corporation (UTHR:NAS)?
Halo FAQ
The current P/E ratio for United Therapeutics Corporation (UTHR:NAS) is 17.50.

See beyond the curve.

One solution for research, investing and portfolio management.